Petosemtamab (MCLA-158) is a human, common light-chain IgG1 bispecific antibody that simultaneously targets the EGFR and the leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5), a cancer stem cell marker [99]. Here, EGFR is linked to cancer.